Home
overview

The conference listed on this page was held in 2004. For information on the 2010 conference go to www.smi-online.co.uk/2010europricing.asp  

European Pharmaceutical Pricing & Reimbursement Conference 2010

  


 

Now in it's tenth year, this is certainly our 'must attend' commercial pharma event. Every year, this event sells out. So please register now to ensure your place at this important industry forum. The agenda includes a full update on new regulatory developments, plus an in-depth analysis of P&R systems in the 5 main European Markets:

  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain

The event includes a series of case studies from the leading pharma companies to illustrate the success and deficiencies of their pricing strategies.

It looks at how companies can go about optimising and expediting the reimbursement process.

The event assesses what the accession markets have been doing since EU enlargement and explores the changes in parallel trade over the last 6 months.

Hear from the latest national policy makers from Germany, UK, Spain and France:
 

  • Ulrich Dietz, Head, Reimbursement Regulation Unit, Bundesministerium für Gesundheit und soziale Sicherung (German Ministry of Health)
  • Jorge Mestre-Ferrandiz, Industrial Economist, Office of Health Economics
  • Dr Antoni Gilabert Perramon, Head of Division, Pharmaceutical Care & Complementary Benefits, Catalan Health Service
  • François Meyer, Secretary General, Transparency Commission, French Health Products Agency (AFSSAPS)


Plus, key industry strategists from across Europe:
 

  • Anne-Toni Rodgers, Director, Government Affairs and Public Policy
  • Europe, Baxter Healthcare
  • Nick Schulze-Solce, Director of Corporate Affairs, Lilly Pharma
  • Dr George Frances, Director, Economy & Regulatory Affairs, Wyeth
  • Anina Fraschke, Head, Price Monitoring Europe, Schering
  • Dr Cristina Espinosa, Head, Health Economics & Outcomes Research, Novartis
  • Martin Egler, Senior Manager, Health & Society, Health Economics, Aventis
  • Marc Benoff, Practice Leader, Pricing & Market Access, IMS Consulting
  • Jim Furniss, Director Pricing & Reimbursement, Bridgehead Technologies
  • Janice Haigh, Consultant, IMS Consulting
  • Donald Macarthur, Secretary General, European Association of Euro-Pharmaceutical Companies


Previous attendees include senior executives from:

Lifescan, Lilly, Allergan, The WHO, Pharmacia, Wyeth-Lederle, AstraZeneca, Leo Pharmaceuticals, Glaxosmithkline, Schering, Procter & Gamble, Janssen, Biogen, The Office Of Health Economics, The Prescription Pricing Authority, Solvay Pharmaceuticals, Alliance Unichem, Elan Pharma, Bristol-Myers Squibb, Covance, Lundbeck, Aventis, Pfizer, ALTANA, Shire Pharmaceuticals, Serono International, Aventis Pasteur MSD, Mckinsey & Company, Merck Sharpe and Dohme, Colgate Oral Pharmaceuticals, The Ministry of Health Finland, Pliva, The Pharmaceutical Manufactures Association, Sanofi-Synthelabo, The Boston Consulting Group, Association of the German Pharmaceutical Industry (BPI), Ministerio de Sanidad y Consumo, Novo Nordisk, IMS, BUPA, PowderJect, Amgen, Procter & Gamble Pharmaceuticals, UK Dept of Health, The Department of Health and Children Ireland, Abbott, Apifarma-Associacao Poruguesa Da Industrria Farmaceutica, French Health Products Agency (AFSSAPS), European Association of EuroPharmaceutical Companies, Baxter Healthcare, and many, many more...

Conference programme

8:30 Registration and Coffee

9:00 Chairperson's Opening Remarks

Janice Haigh

Janice Haigh, Consultant, IMS/Cambridge Management Consultancy

9:10 TRUE GLOBAL PRICING STRATEGIES FOR EU

Martin Egler

Martin Egler, Senior Manager, Health Economics, Corporate Public Affairs, Aventis

  • Pricing and reimbursement regulation
  • Reimbursement structure and organisation healthcare structure
  • Health insurance structure
  • Pricing legislation and policies
  • Legislative reforms
  • Stringent price controls elongated reimbursement decisions slowing down products’ access to market
  • Key trends
    • National and international price referencing, health economics assessment
    • Price discrepancy between international and US markets
  • 9:50 INDUSTRIAL POLICY, INNOVATION AND PRICES

    Jim Furniss

    Jim Furniss, Director, Pricing and Reimbursement, Bridgehead Technologies

  • How could Europe increase its competitive edge in the pharmaceutical playing field?
  • Some positive steps: · Free pricing for innovation · Free pricing for non-reimbursed medicines · Faster market access (in some markets)
  • A single European price – myths and realities
  • Continuing government cost-containment activities: · Reference pricing · Reimbursement restrictions and positive lists · Cost effectiveness hurdles
  • 10:30 Morning Coffee

    11:00 EU ENLARGEMENT

    Anina Fraschke

    Anina Fraschke, Head, Price Monitoring Europe, Schering

  • EU expansion and the pharmaceutical market
  • Parallel importing within the EU
  • International price comparison
  • Price corridor strategies to limit parallel trade
  • Pre-accession harmonisation initiative: the EU mutual recognition procedure
  • Conflict of drug pricing policies and reimbursement post-accession
  • 11:40 GENERIC PRICING

    Dr Ann-Katrin Gonschior

    Dr Ann-Katrin Gonschior, International Product Manager, Corporate Marketing Health Economics, ALTANA Pharma

  • Status of the new pharmaceutical legislation
  • Key issues affecting generic registrations
  • Legal issues affecting the registrations of generic medicines
  • Implications of the Pharma Review on generics in the acceeding countries
  • How will the centralised procedure system work for applications of generics?
  • What effect will the new mutual recognition and decentralised procedure systems have on generics application?
  • Generics after EU enlargement
  • 12:20 Networking Lunch

    13:50 PERSPECTIVES ON PRICING, PURCHASING AND REIMBURSEMENT IN THE UK

    Anne-Toni Rodgers

    Anne-Toni Rodgers, Director, Government Affairs and Public Policy – Europe, Baxter Healthcare

  • The PPRS - current state of play
  • Likely options for the future
  • National approaches to cost effectiveness, NICE (England), AWMSG (Wales) and SMC (Scotland)
  • A look at differences, commonality and implications
  • Commissioning at a national and local level
  • The implications of the PASA reorganisation and reverse tenders
  • G10 - a single EU price?
  • 14:30 PRICING & REIMBURSEMENT IN THE UK MARKET

    Dr Jorge Mestre-Ferrandiz

    Dr Jorge Mestre-Ferrandiz, Industrial Economist, Office of Health Economics

  • Overview of UK generic market
  • The drug tariff
  • 2000 statutory maximum price scheme
  • Department of Health 2003 ‘Generic market consultation document’
  • 15:10 Afternoon Tea

    15:40 GERMANY HAS THE HIGHEST MARKET PRICES

  • Germany’s healthcare system is one of the most expensive in the world
  • How will the healthcare reform affect German Pharmaceutical companies?
  • Enlarged reference price system and cost benefit analysis forces R&D based companies to review their strategy
  • Reform of healthcare financing: citizen insurance vs flat rate insurance fee - is Germany turning to a preferred-provider-system?
  • Ulrich Dietz

    Ulrich Dietz, Head, Reimbursement Regulation Unit, German Ministry of Health

    Ulrich Dietz

    Ulrich Dietz, Head, Reimbursement Regulation Unit, German Ministry of Health

    16:20 HEALTHCARE REFORM: 10 MONTHS’ EXPERIENCES

    Dr Nick Schulze-Solce

    Dr Nick Schulze-Solce, Director Corporate Affairs, Lilly Pharma

  • The new reference pricing scheme: update on implementation
  • Mandatory rebate: status and expectations
  • German “NICE”: where is it, how will it work?
  • The next phase: the overhaul of the whole healthcare financing system - what is to be expected?
  • 17:00 Chairperson's Closing Remarks and Close of Day One

    8:30 Re-registration and Coffee

    9:00 Chairperson's Opening Remarks

    Donald Macarthur

    Donald Macarthur, Secretary General, European Association of Euro-Pharmaceutical Companies (EAEPC)

    9:10 PRICING OVERVIEW

    Dr Georges France

    Dr Georges France, Director, Economy & Regulatory Affairs, Wyeth

  • Pricing of pharmaceuticals and how the reimbursement works
  • The use of international reference pricing
  • The link between therapeutic improvement and price
  • The role of health economics evaluations
  • The ‘Framework Agreement’
  • Generics and the new reference price system
  • Health economic evaluations
  • Margins for wholesalers and pharmacists
  • 9:50 THE NEW TRANSPARENCY COMMISSION

    Dr François Meyer

    Dr François Meyer, Secretary General, Transparency Commission, French Health Products Agency (AFSSAPS)

  • Scientific evaluation of pharmaceuticals in the P&R process
  • 10:30 Morning Coffee

    11:00 WILL THE CHANGE OF GOVERNMENT AFFECT CURRENT PRICING AND REIMBURSEMENT POLICIES?

    Dr Cristina Espinosa

    Dr Cristina Espinosa, Head, Health Economics & Outcomes Research, Novartis

  • Framework for pricing and reimbursement in Spain
  • Generics + reference pricing
  • The role of regions in the rational use of medicines and/or cost-containment measures
  • Focus on innovation, focus on the system, focus on the patient
  • 11:40 THE CATALAN PHARMACEUTICAL CARE MODEL

    Dr Antoni Gilabert Perramon

    Dr Antoni Gilabert Perramon, Head of Division, Pharmaceutical Care & Complementary Benefits, Catalan Health Service

  • Current situation of pharmaceutical services and the decision-making process
  • Point of view about pricing and reimbursement policies
  • Vision in the future
  • 12:20 Networking Lunch

    13:50 OUTLOOK FOR REIMBURSEMENT IN ITALY

    Fabrizio Gianfrate

    Fabrizio Gianfrate, Professor of Health Economics / Vice President & General Manager, University of Ferrara / SmithKline Foundation, Italy

  • Toward cost-benefit classification of patented products
  • Reimbursement classification system
  • Increased regional control and modifications to the system of co-payments
  • Demographics-based co-payment exemptions
  • Product de-listing and industry paybacks
  • Price caps and a new reimbursement class for generics
  • National and regional product de-listing
  • Industry paybacks
  • Pharmacoeconomics policies in Italy
  • 14:30 PANEL DISCUSSION

    Martin Egler

    Martin Egler, Senior Manager, Health Economics, Corporate Public Affairs, Aventis

    Dr Cristina Espinosa

    Dr Cristina Espinosa, Head, Health Economics & Outcomes Research, Novartis

    Dr Georges France

    Dr Georges France, Director, Economy & Regulatory Affairs, Wyeth

    Donald Macarthur

    Donald Macarthur, Secretary General, European Association of Euro-Pharmaceutical Companies (EAEPC)

    15:10 Afternoon Tea

    15:40 HOW DOES EUROPE COMPARE TO THE US?

    Ian Bradley

    Ian Bradley, Consulting Leader, Cambridge Pharma Consultancy

  • Current issues
    • Greater pressure from private insurers
    • Reduced health insurance affordability
    • Limited price transparency
  • Regulatory action
    • State governments enforce lower drug prices for the uninsured
    • Implementation of parallel trading
  • Medicare reform controversies
  • Strategic options to maintain profitability
    • Retain international market share
    • Implement cost reduction strategies
    • Effectively manage the innovative therapeutics pipeline
  • 16:20 OVERVIEW OF PRICING AND REIMBURSEMENT IN CANADA

    W Neil Palmer

    W Neil Palmer, Principal, Palmer D’Angelo Consulting, Canadian Industry Representative (TBD)

  • Price controls & patented medicine prices review board (PMPRB)
  • Public reimbursement and the evolving "Common Drug Review"
  • Role of pharmacoeconomics and outcomes research
  • Prospects for "National Pharmacare"
  • Implications of Canada/US cross-border (parallel) trade
  • 17:00 Chairperson's Closing Remarks

    Close of Conference

    +

    Workshops

    Changes in Parallel Trade in the last 6 months since EU Enlargement
    Workshop

    Changes in Parallel Trade in the last 6 months since EU Enlargement

    Park Street Training and Meeting Centre, at etc. venues
    26th October 2004
    London, United Kingdom

    Pricing in the USA
    Workshop

    Pricing in the USA

    Park Street Training and Meeting Centre, at etc. venues
    29th October 2004
    London, United Kingdom

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.